In the case of bluebird, they did, according to Morgan Stanley analyst Matthew Harrison and team, who downgraded its shares to Underweight from Equal Weight. (NASDAQ:KITE) by 61.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). They now have a Dollars 95 price target on the stock. With 3.80M shares average volume, it will take short sellers 1 days to cover their KITE's short positions. Sheaff Brock Investment Advisors LLC purchased a new position in Kite Pharma during the 2nd quarter valued at about $238,000.
Ratings analysis reveals 60% of Kite Pharma's analysts are positive.
Traders are a little more bullish on shares of the company of late at least if you consider the change in short interest. Pacer Advisors Inc. raised its holdings in Kite Pharma by 22.7% in the 2nd quarter. BlackRock Inc. now owns 3,995,272 shares of the biopharmaceutical company's stock worth $414,190,000 after buying an additional 373,301 shares during the period. The ROIC 5 year average of Kite Pharma, Inc. The institutional investor owned 38,693 shares of the biopharmaceutical company's stock after selling 1,922 shares during the period. The California-based Partner Fund Management L.P. has invested 4.87% in the stock.
COPYRIGHT VIOLATION NOTICE: This news story was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this article on another site, it was stolen and reposted in violation of US and worldwide trademark and copyright legislation. Moreover, Deutsche Natl Bank Ag has 0.02% invested in Kite Pharma Inc (NASDAQ:KITE).
The share price of Kite Pharma, Inc. The stock price hovered in an intraday range of $5.93- $6.01. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Amalgamated Bank grew its stake in shares of Kite Pharma by 17.8% during the second quarter. The 20-day RSI for KITE is 86.57%, which suggests that the stock may be primed for a trend reversal or a corrective pullback in price. Following the completion of the sale, the chief operating officer now owns 132,795 shares in the company, valued at approximately $13,689,836.55. The disclosure for this sale can be found here. The shares were sold at an average price of $179.66, for a total value of $4,733,502.02. Kite Pharma, Inc. has a 52-week low of 39.82 and a 52-week high of 179.95. Kite Pharma, Inc. The firm's market cap is $10.28 billion. They now have a United States dollars 85 price target on the stock. (NASDAQ:KITE) was up +0.00% during the last trading session, with a day high of 179.95. The biopharmaceutical company reported ($1.94) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.97) by $0.03. The Return on Equity (ROE) value stands at -59.6%. The difference between the expected and actual EPS was $0.04/share, which represents an Earnings surprise of 2%. The firm's revenue for the quarter was up 110.4% compared to the same quarter previous year.
Stock market analysts and brokers have recently amended their target prices on shares of Kite Pharma, Inc. NasdaqGS:KITE is -0.15662. This number is calculated by looking at the sum of the dividend yield plus percentage of sales repurchased and net debt repaid yield.
Kite Pharma, Inc is a clinical-stage biopharmaceutical company.
08/29/2017 - Kite Pharma, Inc. was downgraded to "hold" by analysts at Canaccord Genuity. Analysts reported that the Price Target for Kite Pharma, Inc. might touch $180 high while the Average Price Target and Low price Target is $170.38 and $128 respectively. Out of 5 Wall Street analysts rating Kite Pharma, 3 give it "Buy", 0 "Sell" rating, while 2 recommend "Hold".
During the recent trading sessions stock of Kite Pharma, Inc. Fourteen research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. The Firm is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Firm offers engineered autologous cell therapy, which is an approach to the treatment of cancer.